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Hypercholesterolemia is a frequent metabolic disorder associated with increased risk for cardiovascular morbidity and mortality.
In addition to its well-known proatherogenic effect, hypercholesterolemia may exert direct effects on the myocardium resulting
in contractile dysfunction, aggravated ischemia/reperfusion injury, and diminished stress adaptation. Both preclinical and
clinical studies suggested that elevated oxidative and/or nitrative stress plays a key role in cardiac complications induced by
hypercholesterolemia. Therefore, modulation of hypercholesterolemia-induced myocardial oxidative/nitrative stress is a feasible
approach to prevent or treat deleterious cardiac consequences. In this review, we discuss the effects of various pharmaceuticals,
nutraceuticals, some novel potential pharmacological approaches, and physical exercise on hypercholesterolemia-induced
oxidative/nitrative stress and subsequent cardiac dysfunction as well as impaired ischemic stress adaptation of the heart in
hypercholesterolemia.
1. Introduction
Hypercholesterolemia, a frequent form of hyperlipidemia, is
a metabolic disorder characterized by elevated levels of total
cholesterol in the blood. Hypercholesterolemia may develop
as a consequence of unbalanced diet, obesity, inherited
(genetic) diseases (familial hypercholesterolemia), or other
diseases (e.g., diabetes). According to large clinical stud-
ies, hypercholesterolemia affects a significant population of
adults in developed countries [1]. For instance, approximately
100 million people (44.4%) suffered from hypercholestero-
lemia (>5.2mmol/L) in the United States in 2008 [2]. The
relationship between hypercholesterolemia and cardiovas-
cular mortality has been known for decades [3]. Hyper-
cholesterolemia, especially elevated low density lipoprotein
(LDL) cholesterol, is a major risk factor for the devel-
opment of atherosclerosis and subsequent ischemic heart
disease [4], which is a leading cause of death worldwide [5].
Moreover, several experimental studies have demonstrated
that, in addition to its well-known proatherogenic effect
in the vasculature, hypercholesterolemia may directly affect
the heart causing contractile dysfunction [6–8], aggravated
ischemia/reperfusion injury [9], and attenuated responses
to cardioprotective interventions including ischemic pre-
and postconditioning [10, 11]. Although the pathoetiology of
hypercholesterolemia has been studied extensively, the pre-
cise molecular mechanisms leading to cardiac complications
are not entirely clear. Nevertheless, substantial evidence exists
demonstrating that hypercholesterolemia induces oxidative
and nitrative stress in the heart and that oxidative/nitrative
stress plays a role in several cardiac pathologies. Therefore,
modulation of oxidative stress in the hypercholesterolemic
myocardium appears to be a rational approach. In this review
we aim to discuss relevant literature related to potential
modulation of hypercholesterolemia-induced oxidative stress
and subsequent complications in the heart (Figure 1). Our
attention is focused on certain pharmaceuticals, nutraceuti-
cals, novel pharmacological approaches, and physical exercise
as potential modulators.
2. Hypercholesterolemia and
Oxidative/Nitrative Stress
Oxidative/nitrative stress can be defined as an excess for-
mation or insufficient removal of highly reactive molecules
such as reactive oxygen and/or nitrogen species (ROS and
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Figure 1: Hypercholesterolemia-inducedmyocardial oxidative/nitrative stress and its possible modulations (in grey boxes) to prevent or treat
deleterious cardiac consequences. Ac-CoA: acetyl-coenzyme A; HMG-CoA: 3-hydroxy-3-methyl glutaryl coenzyme A; eNOS: endothelial
nitric oxide synthase; ONOO−: peroxynitrite; ROS: reactive oxygen species; RNS: reactive nitrogen species; miRNA: microRNA.
RNS, resp.) including, for instance, superoxide, hydrogen
peroxide, hydroxyl radical, and peroxynitrite [12]. Enzymatic
sources for ROS formation include the mitochondrial respi-
ratory chain, nicotinamide adenine dinucleotide phosphate
(NADPH) oxidases, xanthine oxidase, cyclooxygenases,
uncoupled nitric oxide synthase (NOS), and peroxidases,
while antioxidant enzymatic systems include superoxide dis-
mutase (SOD), catalase, glutathione peroxidase, glutathione
reductase, and heme oxygenase (HO) [13]. Although there
is a consensus in the literature that hypercholesterolemia is
associated with increased cardiac oxidative stress (Figure 1),
the precise molecular mechanisms by which hypercholes-
terolemia induces oxidative stress in the heart are not entirely
clear. Accumulating evidence shows increased superoxide
production in the hearts of hypercholesterolemic animals,
and one of the major sources of this superoxide appears to be
increased NADPH oxidase activity in cholesterol-fed Wistar
rats and apoB100 transgenic mice [6, 8]. In the hearts of
cholesterol-fed CFLP mice and Wistar rats, transcript levels
of NADPH oxidase 4 (NOX4) were significantly increased
when compared to normal controls fed a standard chow
[8, 14]. The increased NOX4 transcript levels in hypercholes-
terolemic hearts can be related to transcriptional, posttran-
scriptional, or epigenetic regulation of NOX4 expression.
One study shows an association of cardiac NOX4 transcript
and protein levels as well as NADPH oxidase activity with
decreased myocardial level of the microRNA miR-25 in
rats with diet-induced hypercholesterolemia [8]. MicroRNAs
(miR or miRNA) are endogenous, small, noncoding RNAs
that are responsible for posttranscriptional silencing of a
wide variety of specific target genes. NOX4 was identified
as a direct target of miR-25, suggesting that decreased miR-
25 allows the upregulation of NOX4, which contributes to
increased ROS production in the hypercholesterolemic heart
[8]. Although alterations in cardiac gene expression have
been demonstrated in animal models of diet-induced hyper-
cholesterolemia [14, 15] and metabolic syndrome [16], to the
best of our knowledge, the precise molecular link between
hypercholesterolemia and altered cardiac gene expression has
not yet been elucidated. Interestingly, two key transcriptional
factors have been implicated to date in cholesterol-dependent
transcriptional regulation of gene expression, that is, the
sterol-regulatory element binding protein (SREBP) and the
liver X receptor (LXR) [17]; however, direct evidence for their
role in hypercholesterolemia-induced oxidative stress is still
lacking.
Another possible explanation for increased oxidative
stress could be diminished endogenous antioxidant capac-
ity. Indeed, hypercholesterolemia has been reported to be
associated with decreased cardiac expression and activity
of antioxidant enzymes [18–21]. Nevertheless, the precise
molecular mechanisms by which high cholesterol downreg-
ulates myocardial antioxidant enzymes remain to be elu-
cidated. Besides enzymatic mechanisms, tissue level of the
endogenous antioxidants is also an important determinant of
oxidative/nitrative stress. Nitric oxide (NO) is a key antioxi-
dant molecule that is synthesized by NO synthases in various
cells including cardiomyocytes. In the hearts of hypercholes-
terolemic animals, cardiac NO level was decreased when
compared to controls [10, 22, 23]; however, this effect was
independent of the modulatory effect of cholesterol on the
mevalonate pathway [23]. Moreover, transcript levels of NOS
Oxidative Medicine and Cellular Longevity 3
3 were decreased, while NOS 1 and 2 remained unaffected in
the hearts of cholesterol-fed mice [14].
In addition to the effects of cholesterol and its derivatives
on gene expression, membrane-related effects of cholesterol
are also plausible [39]; however, these effects have barely been
investigated in the hypercholesterolemic heart.
3. Functional Effects of
Hypercholesterolemia on the Heart
Hypercholesterolemia has been shown to exert direct
myocardial effects independent of the development of
atherosclerosis in both clinical [40, 41] and preclinical
studies [7, 8]. These effects include impaired cardiac per-
formance and contractile dysfunction [6, 7], aggravated
ischemia/reperfusion injury [9], and diminished adaptation
to ischemic stress [10, 11, 42] (Figure 1).
3.1. Cardiac Contractile Dysfunction. Observations in human
clinical trials and animal models suggest a direct effect of
cholesterol on myocardial contractile function leading to
impaired diastolic and in some cases also systolic function [6–
8, 43–45]. Although the symptoms of hypercholesterolemia
are not pronounced initially and the disordermay be dormant
for a long time, preclinical diastolic dysfunction shows a clear
progression to heart failure [46].Development of heart failure
aggravates with advancing age and contributes to age-related
morbidity and mortality [47].
The direct effects of cholesterol exposure on cardiomy-
ocyte functionwere demonstrated in a cell culturemodel; that
is, elevation of membrane cholesterol content in ventricular
cardiomyocytes resulted in decreased cytosolic calcium levels
and impaired cardiac myocyte contractility [48]. This has
been confirmed in cholesterol-fed rabbits and rats, showing
apparent contractile dysfunction characterized by decreased
maximum rate of shortening, decreased rate of relaxation,
and increased left ventricular end-diastolic pressure [7, 8, 10,
44]. Moreover, impairment of cardiac performance assessed
by measuring aortic flow was also demonstrated in hearts
isolated from hypercholesterolemic apoB100 transgenic mice
[6]. Hypercholesterolemia-induced cardiac dysfunction was
further confirmed by echocardiography in humans [43, 45,
49].
It has been shown previously that myocardial oxida-
tive/nitrative stress induced by hypercholesterolemia signifi-
cantly contributes to the development of cardiac dysfunction
[6, 8, 50]. However, the exact underlying molecular mech-
anisms are still not entirely clear. One possible mechanism
is the oxidation of contractile proteins [8, 51, 52]. In failing
human heart samples, for instance, there is an obvious oxi-
dation and nitrosylation of tropomyosin and actin, showing
a positive correlation with diminished contractile function
indicated as a decrease in ejection fraction [51]. Moreover,
increased protein oxidation was confirmed in the hearts of
hypercholesterolemic rats [8].
3.2. Aggravated Ischemia/Reperfusion Injury and Attenuated
Stress Adaptation. Hypercholesterolemia facilitates the risk
of atherosclerosis and subsequent myocardial infarction.
The current treatment of myocardial infarction includes the
attempt to reopen the occluded coronary artery (termed
reperfusion) in a timely manner by coronary interven-
tion procedures or thrombolytic therapies in order to
reduce infarct size, which is one of the major deter-
minants of long term complications and survival. Thus
the majority of patients with acute myocardial infarc-
tion undergo ischemia/reperfusion injury. However, the
myocardium is remarkably good at adapting to ischemic
conditions by triggering endogenous adaptive mechanisms
against ischemia/reperfusion injury. One of the most pow-
erful endogenous adaptive cardioprotective mechanisms is
ischemic preconditioning, that is, when brief exposure to
repetitive ischemia/reperfusion cyclesmarkedly enhances the
ability of the heart to withstand a subsequent, potentially
lethal ischemic attack [53]. Another possible intervention is
termed ischemic postconditioning when the initial phase of
reperfusion is interrupted with short periods of ischemia
[54]. In addition, remote conditioning has also been intro-
duced when cardioprotection is achieved by exposing an
organ at a distance from the heart to ischemia/reperfusion
insults [55]. To date, a very large number of preclinical
and clinical studies are available suggesting that hypercho-
lesterolemia enhances the severity of ischemia/reperfusion
injury and interferes with the endogenous cardioprotec-
tive mechanisms. The mechanisms of ischemia/reperfusion
injury and endogenous cardioprotection as well as the effect
of hypercholesterolemia on these phenomena have been
extensively reviewed elsewhere [56–58].
4. Modulation of Hypercholesterolemia-
Induced Oxidative/Nitrative Stress
Modulation of oxidative/nitrative stress in hypercholes-
terolemia can be approached by at least 3 different ways
(Figure 1). First, cholesterol-lowering therapies should be
effective in attenuation of oxidative/nitrative stress due to
their trigger-eliminating effect. Second, the mechanism of
action of several drugs used for cholesterol-lowering is
complex and may involve antioxidant properties. The second
approach may be the most obvious, that is, the application
of antioxidant molecules and especially natural products to
reduce oxidative/nitrative stress. Third, support or induction
of endogenous enzymatic antioxidant systems or inhibition
of the prooxidant enzymes may be a feasible way to control
cardiac oxidative/nitrative stress in hypercholesterolemia.
These distinct mechanisms of action are often combined in
the case of certain modulators. In this section we discuss var-
ious pharmaceuticals, nutraceuticals, some novel approaches,
and even physical exercise as potential modulators of
hypercholesterolemia-induced oxidative/nitrative stress.
4.1. Pharmaceuticals. To the best of our knowledge, there are
no drugs on themarket approved to specifically target cardiac
oxidative/nitrative stress induced by hypercholesterolemia.
Nevertheless, cholesterol-lowering drugs are excessively pre-
scribed for patients presenting hypercholesterolemia and
due to their cholesterol-lowering effect they should have
4 Oxidative Medicine and Cellular Longevity
a secondary attenuating effect on hypercholesterolemia-
induced oxidative/nitrative stress. Interestingly, several of
these drugs have also been implicated in directly modulating
oxidative/nitrative stress. Moreover, large clinical trials have
shown that antihyperlipidemic agents, for example, statins
[59], fibrates [60], and niacin [61], could reduce the incidence
of cardiovascular events in hypercholesterolemic patients
[59]. In addition, some drugs used for other indications than
treatment of hypercholesterolemia (e.g., some antidiabetics
and vasodilators) have also been demonstrated to attenuate
hypercholesterolemia-induced oxidative/nitrative stress and
deleterious cardiac consequences.
4.1.1. Statins. Statins are a class of cholesterol-lowering drugs
that inhibit the key enzyme, 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, of the endogenous
cholesterol biosynthesis. Statins have therefore become estab-
lished in the treatment of hypercholesterolemia and attained
a central place in cardiovascular medicine [62]. However,
there are potential side effects of statin therapy including
skeletal muscle complaints and/or mild elevation of serum
creatine kinase level and very rarely rhabdomyolysis [63].
The main members of statins on the market are lovastatin,
rosuvastatin, simvastatin, atorvastatin, fluvastatin, pravas-
tatin, and the newest addition, pitavastatin. By inhibition
of the formation of mevalonate, the direct reaction product
of HMG-CoA reductase and HMG-CoA, statins not only
inhibit the formation of the end-product, cholesterol, but
also they reduce the formation of other cholesterol pathway
intermediers such as the 15-carbon isoprenoid farnesol or the
20-carbon isoprenoid geranylgeraniol which finally lead to
reductions in protein prenylation, Coenzyme Q10 (see later),
and dolichol synthesis. Besides lipid-lowering effects, statins
have pleiotropic effects on different cell types. Some of these
cholesterol-independent effects of statins involve improved
endothelial function, stabilization of atherosclerotic plaques,
and attenuation of oxidative stress and inflammation as
well as inhibition of the thrombogenic response [64, 65].
Pleiotropic effects may play an important part in reducing
cardiovascular mortality and morbidity and may act at
multiple points in the complex cascade of events leading to
atherosclerosis.
Regarding the antioxidative effect of statins, a recent
study showed that, beside the cholesterol-lowering effect,
simvastatin is able to ameliorate endothelial dysfunction
through increasing NO bioavailability and through suppres-
sion of oxidative stress in a ratmodel of hypercholesterolemia
[66]. Similar results were shown by Iliodromitis et al.,
[67] who found that a 3-week simvastatin treatment limits
infarct size and attenuates oxidative and nitrosative stress
both in normocholesterolemic and in hypercholesterolemic
rabbits subjected to ischemia/reperfusion irrespective of the
presence of postconditioning, while postconditioning was
effective only in normocholesterolemic animals. According
to another study [68], pravastatin, in contrast to same-
dose simvastatin or postconditioning, was found to reduce
infarction in hypercholesterolemic rabbits independently of
lipid-lowering, potentially through eNOS activation and
attenuation of oxidative/nitrative stress. The antioxidative
effect of atorvastatin was also shown by several studies [69–
72]. Moreover, in hyperlipidemic subjects with metabolic
syndrome, atorvastatin is associated with a greater reduction
in lipid markers of oxidation compared with pravastatin [73].
In contrast, Sodha et al. [74] found increased levels ofmyocar-
dial biomarkers of oxidative stress in hypercholesterolemic
swine treated with atorvastatin. Pitavastatin, the newest
member of the HMG-CoA reductase inhibitor family, has
shown improvements in both cardiovascular function and
markers of oxidative stress [75], presumably via decreasing
NADPH oxidase activation [64]. Fluvastatin was also shown
to play a protective role against high-cholesterol-induced
oxidative stress and DNA damage [76]. Taken together, the
cardioprotective effect of almost every statin is associated
with some pleiotropic effect which can decrease oxidative
stress in the cardiovascular system.
4.1.2. Ezetimibe. Ezetimibe, another lipid-lowering drug, is
used in monotherapy or in combination with statins and
is responsible for lowering intestinal cholesterol absorption
by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) sterol
transporter. Clinical studies showed that ezetimibe attenuates
the markers of oxidative stress in hyperlipidemic subjects
[77–80]. The drug is suggested to exert both cholesterol-
dependent and independent actions [78–80]. Reduction of
serum cholesterol results in decreased cholesterol influx
to the cells thereby attenuating cholesterol-induced oxida-
tive stress. For instance, ezetimibe reduced hepatic choles-
terol level in obese male mice which in turn attenuated
oxidative stress via downregulation of NADPH oxidases,
cytochrome P4502E1, and beta oxidation [81]. In addition
to its cholesterol-lowering action, ezetimibe may exert a
direct cholesterol-independent effect on cells [78–80, 82].
A feasible explanation is that NPC1L1 is widely expressed
in many other tissues including liver, kidney, muscle, and
heart [83]. Cell culture studies support the possible direct
effect of ezetimibe on cellular oxidative/nitrative stress, for
example, knockdown of NPC1L1 in hepatocytes attenuated
ROS production [84]. Based on these findings it is plausible
to speculate that ezetimibe has a direct impact on the
heart and may decrease cholesterol-induced oxidative stress.
Nevertheless, direct cardioprotective effect of ezetimibe has
not yet been investigated in the literature; thus preclinical
studies needed to address this issue.
4.1.3. Niacin. Although niacin (nicotinic acid or Vit B
3
) is
a potent lipid-lowering agent when used in pharmacologic
doses, its clinical use is limited by side effects, so it can
be applied particularly in combination to treat marked
dyslipidemia with strict monitoring ([85], for review see
[86]). Niacin administration was shown to reduce markers of
serum oxidative stress and increase antioxidant paraoxonase-
1 in patients with hypercholesterolemia [87]. A randomized
controlled clinical trial reported that niacin improves both 6-
and 15-year mortality of patients after myocardial infarction
with or without metabolic syndrome thereby suggesting a
cardioprotective effect for niacin [88].Direct cardioprotective
effect of niacin was reported in preclinical studies as well
[89–92]. However, evidence is not available to clarify the
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potential beneficial effect of niacin in cholesterol-induced
cardiac stress.
4.1.4. Fibrates. Fibrates (amphipathic carboxylic acid deriva-
tives) lower plasma triglyceride and small LDL level and
increase high density lipoprotein (HDL) concentration; thus
fibrates are particularly used to treat combined dyslipidemia
related to diabetes or metabolic syndrome [93]. This class
of drugs acts on nuclear peroxisome proliferator-activated
receptor 𝛼 (PPAR𝛼), leading to transcriptional changes [94].
Studies revealing the effect of fibrates on cholesterol-induced
cardiac oxidative stress are not available in the literature. Nev-
ertheless, some investigations have reported an antioxidant
effect of fibrates. A subcohort clinical trial has demonstrated
that 3-week fenofibrate treatment reduced ox-LDL and 8-
isoprostane, systemic markers of oxidative stress in patients
with hypertriglyceridemia [95]. In accordance with these
results, fenofibrate decreased ox-LDL with a modest reduc-
tion in cholesterol level in healthy normolipidemic older
adults [96]. Fibrates may exert antioxidant actions indepen-
dently from their lipid-lowering effect. For instance, Sugga et
al. have reported that in vivo administration of fenofibrate and
clofibrate before ex vivo myocardial ischemia/reperfusion
reduced infarct size and oxidative stress [97]. Others have
shown antioxidant and cardioprotective effects of fibrates
against development of ventricular hypertrophy associated
with oxidative stress [98, 99]. Furthermore, fibrates prevent
endothelial dysfunction by ameliorating oxidative stress,
without affecting plasma lipid levels [100, 101]. It has been
also published that knockout of PPAR𝛼, the ligand of fibrates,
leads to oxidative stress associated with cardiac dysfunction
[102]. In contrast, fenofibrate failed to improve lipotoxic
cardiomyopathy [103], and high dose fibrate induced cardiac
damage in healthy rats [104]. Taken together, the studies
focusing on antioxidant action of fibrates suggest a potential
beneficial effect on cholesterol-induced cardiac oxidative
stress, although this needs to be confirmed in further studies.
4.1.5. Other Pharmaceuticals. There are some available drugs,
which are basically used to treat other diseases than hyper-
cholesterolemia and which have beneficial effects on high-
cholesterol-induced cardiac consequences.
Rosiglitazone is an antidiabetic drug; however, it also
improves blood cholesterol level in hypercholesterolemic
models [105, 106]. It was reported that the drug pre-
vents the development of high-cholesterol-induced cardiac
hypertrophy [105] and ameliorates postischemic recovery
and nitrative stress in the heart of high-cholesterol-fed
rabbits [107]. The latter research group has also shown
that rosiglitazone alleviates aggravated postischemicmyocar-
dial injury and myeloperoxidase upregulation caused by
hypercholesterolemia, independently from the lipid-lowering
action [108]. Rosiglitazone has a direct antioxidant effect
on cardiomyocytes [109] and has been demonstrated to
prevent the upregulation of cardiac NOX4 in a high-fat high-
sugar diet, streptozotocin-induced diabetic model associated
with dyslipidemia [110]. These findings make rosiglitazone a
promising modulator of cholesterol-induced cardiac oxida-
tive stress.
Increasing the level of glucagon-like peptide-1 by admin-
istration of analogues or by inhibiting dipeptidyl peptidases is
used for the treatment of diabetes and has recently emerged
as a potential cardioprotective approach [111]. Specifically, a
glucagon-like peptide-1 agonist was shown to reverse cardiac
dysfunction induced by high-fat diet [112] and a dipeptidyl
peptidase inhibitorwas found to improve cardiac dysfunction
and oxidative stress in high-fat high-fructose-fed mice [113].
The vasodilator fasudil (a potent rho kinase inhibitor)
was shown to lower serum cholesterol level and decrease
cardiac oxidative stress by enhancing antioxidants in hyperc-
holesterolemic rat hearts [114]. The group has reported that
fasudil restores cardiac eNOS and NO level diminished by
high-cholesterol diet [114]. Interestingly, even in the state of
hypercholesterolemia, fasudil can induce both precondition-
ing and postconditioning [115]. Moreover, fasudil restores the
cardioprotective effect of ischemic postconditioning in rats
with hypercholesterolemia [116].
4.2. Nutraceuticals. In spite of the extensive research in
cardiology, particularly in ischemic heart diseases, only
very few new cardioprotective drugs have found their way
into clinical practice [117]. Therefore, there is a growing
interest in nutraceuticals to treat and also prevent certain
cardiac diseases or restore the injured adaptation of the
heart. Nutraceuticals is a term that refers to a wide range
of products including but not limited to natural herbal
products, dietary supplements, isolated nutrients, and special
diets. Since there is also a growing desire among potential
customers to consume natural dietary products instead of
chemically synthesized compounds, the importance of these
nutraceuticals is being further emphasized.
Natural food substances have the potential to alter bio-
logical functions of the cells by mechanisms enhancing the
endogenous antioxidant systems or through altering the
redox signaling status of the cell. This is often related to the
unique composition of different antioxidant compounds in
the various nutraceuticals.These products could be beneficial
in pathological conditions where oxidative stress plays an
important role.
4.2.1. Antioxidant Vitamins. A number of preclinical stud-
ies have demonstrated that classical antioxidant vitamins
including beta carotene (Vit A precursor), folic acid (Vit
B
9
) vitamin C, and vitamin E administered alone or in
combination with other drugs or in multivitamin prepa-
rations could improve serum lipid profile and myocardial
oxidative/nitrative stress in hypercholesterolemia [18, 118–
126]. Moreover, low dose beta carotene has been shown to
improve cardiac function and reduce myocardial oxidative
stress after ischemia/reperfusion injury in hearts of rats [63].
In contrast, vitamin C alone or combined with vitamin E
failed to reducemyocardial infarct size in an open chest rabbit
model [127]. Indeed, Trolox, a vitamin E analogue did not
reduce infarct size but accelerated functional recovery after
myocardial infarction in porcine hearts [128]. In addition,
we have previously shown that a multivitamin preparation
supplemented with phytosterols decreased serum choles-
terol level in hypercholesterolemic rats; however, it did
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not reduce infarct size either in normocholesterolemic or
in hypercholesterolemic hearts of rats [118]. In contrast,
preconditioning with vitamin E has been shown to improve
postischemic contractile and vascular functions in hearts of
rats after ischemia/reperfusion injury [129]. To the best of
our knowledge, the effects of antioxidant vitamins have not
been tested on cardioprotection conferred by ischemic pre-
or postconditioning. However, decrease of oxidative/nitrative
stress by antioxidant vitamins could be a potential therapeutic
target in the restoration of cardioprotective adaptive mecha-
nisms lost in hypercholesterolemia.
Despite a number of preclinical studies proving beneficial
effects of antioxidant vitamins on cardiac pathologies in
hypercholesterolemia, clinical trials investigating the effects
of antioxidant vitamins on cardiovascular morbidity and
mortality have been disappointing.The complex reasons that
might explain the translational failures of preclinical results
into clinical therapy are discussed in detail in recent reviews
[130–132] and include the following: (i) oxidative/nitrative
stress is just a late consequence of cardiac pathologies and
not the primary cause; (ii) pathogenesis of cardiovascular
diseases is complex and increased oxidative/nitrative stress is
not the only cause of these disorders; (iii) antioxidant vitamin
therapy is not able to reduce oxidative/nitrative stress due to
inappropriate study design (inappropriate patient selection,
failure in the administration route, suboptimal time and
duration of antioxidant therapy, poor target specificity, and
potential interaction with other drugs, etc.); (iv) a single
antioxidant therapy is not enough to overcome increased
oxidative/nitrative stress; (v) antioxidant molecules might
have harmful effects on physiological processes or com-
pensatory mechanisms in pathologic conditions induced by
oxidative/nitrative stress.
The lack of beneficial effects of antioxidant vitamins
on cardiovascular pathologies in clinical trials does not
disprove that oxidative/nitrative stress plays a crucial role in
cardiac pathologies in hypercholesterolemia. These clinical
trials challenge us to develop better antioxidant approaches
and better preclinical models as well as to design more
appropriate clinical trials considering the aforementioned
reasons of translational failure.
4.2.2. Coenzyme Q. Coenzyme Q10 (CoQ10), also called
ubiquinone or ubiquinol, is an isoprene derivative and an
alternative product of the mevalonate/cholesterol pathway.
CoQ10 is an endogenous nonenzymatic lipophilic antioxi-
dant and free radical scavengingmolecule playing a role in the
mitochondrial electron transport in the inner mitochondrial
membrane [133]. Moreover, CoQ10 has been reported to play
part in many levels of the redox control of cellular signaling;
in fact the autoxidation of its semiquinone form, generated
in various membranes during electron transport, can be a
primary source for hydrogen peroxide production, which
activates transcription factors [134]. Due to its localization in
themitochondria, it plays a key role in the cellular bioenerget-
ics especially in tissues with high energy requirements such
as the myocardium which is extremely sensitive to CoQ10
deficiency [133, 135]. CoQ10 has been shown to decrease
the levels of proinflammatory cytokines and to reduce LDL
oxidation and consequently the progression of atheroscle-
rosis. It also decreased ischemia/reperfusion injury after
myocardial infarction [135, 136]. Significant improvement has
been demonstrated in clinical and hemodynamic parameters
and in exercise tolerance in patients given adjunctive CoQ10
in various trials conducted in patients suffering from heart
failure, hypertension, ischemic heart disease, and other car-
diac illnesses [135–137].Therefore, CoQ10 could be a potential
therapeutic molecule in heart diseases.
Due to the common biosynthetic pathway of cholesterol
and CoQ10, the HMG-CoA reductase inhibitor statins may
potentially reduce the levels of CoQ10 in different tissues
[138]. Indeed, it has been reported that CoQ10 levels in the
plasma, platelets, and lymphocytes were decreased after statin
treatment [138]. Some papers indicated that CoQ10 depletion
during statin therapy might be associated with subclinical
cardiomyopathy and this situation is reversed upon CoQ10
treatment [138]. In contrast, a preclinical study reported
that coadministration of CoQ10 with simvastatin impaired
mitophagy and cardioprotection after ischemia/reperfusion
injury in mice and cardiomyocytes [139]. These results raise
the concern that CoQ may interfere with the anti-ischemic
benefit of statinsmediated through stimulation ofmitophagy.
Therefore, patients treated with statins should be also mon-
itored for their CoQ10 status and clinicians should be aware
of the aforementioned interaction between statins andCoQ10
as well as the ability of statins to impair skeletal muscle and
myocardial bioenergetics [138].
4.2.3. Flavonoids. Flavonoids are a large family of natural
polyphenolic compounds in the human diet and their benefi-
cial effect on cardiovascular diseases is widely studied. These
compounds favorably affect a wide range of biological pro-
cesses. Beside their antioxidant capacity, flavonoids improve
lipid profile and have anti-inflammatory, antiplatelet, and
antithrombotic effects as well.
Green Tea Catechins (GTC). Catechins are abundant polyphe-
nols in green tea. GTC were shown to reduce blood choles-
terol level in both animals [140–143] and humans [144–
147]. In addition, GTC reduced accumulation of cholesterol
in the rat myocardium in a state of diabetic dyslipidemia
[141]. In a double-blind, placebo-controlled clinical study,
obese, hypertensive patients had decreased LDL-cholesterol
and increased HDL and total serum antioxidant levels after 3
months of GTC supplementation [148]. Mehra et al. demon-
strated that catechin hydrate improvedhigh sucrose, high-fat-
induced cardiac lipid peroxidation and activity of antioxidant
enzymes [149]. GTCwere reported to beneficially affect high-
fructose diet-associated hypercholesterolemia and cardiac
signaling pathways related to lipid metabolism and inflam-
mation [150]. Age-related cardiac oxidative stress was also
improved by GTC [151]. The effect of GTC on hypercholes-
terolemia associated with cardiac dysfunction is not known,
but it was reported thatGTCamelioratesmyocardial function
after ischemia [152, 153] in pressure-induced chronic heart
failure [154] and in autoimmune myocarditis as well [155].
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Troxerutin. Troxerutin can be isolated from the Japanese
pagoda tree (Sophora japonica). To the best of our knowledge,
the antioxidant effect of troxerutin on the heart was first
described in an ischemia/reperfusion model [156]. Geetha
et al. have investigated the cardiac impact of troxerutin in
high-fat high-fructose mice model. They have found that
troxerutin reduces cholesterol content and oxidative stress
markers in both the plasma and the heart and increases
cardiac enzymatic and nonenzymatic antioxidant levels [157].
Moreover, the same group have shown in the same dyslipi-
demic model that troxerutin reverses fibrotic changes in the
heart and improves cardiac function probably by reducing
ROS production [158].
Quercetin.The cardioprotective effect of the dietary flavonoid
quercetin (found in many fruits, vegetables, leaves, and
grains) against ischemia/reperfusion injury is well studied
[159–163]; however, few studies are available in the litera-
ture regarding the impact on hypercholesterolemia-induced
oxidative stress in the heart. It was reported that quercetin
ameliorates left ventricular function, collagen deposition, and
inflammatory cell infiltration in rats with metabolic syn-
drome [164]. In that study, quercetin increased the expression
of the transcription factor Nrf2 and the enzyme heme oxy-
genase as protective proteins against oxidative stress. Inter-
estingly, quercetin exerted a cardioprotective effect without
reducing plasma cholesterol level thereby suggesting a direct
cardiac effect. In other studies, quercetin has been shown
to reduce serum LDL and increase HDL cholesterol level in
hypercholesterolemic rats [165] and lower total cholesterol
in rabbits fed a high-cholesterol [166] and high-fat [167]
diet. Ulasova et al. showed that quercetin improves lipid
profile of ApoE knockout mice and prevents ventricular
hypertrophy without affecting myocardial function [168]. In
a cadmium-induced toxicity study, quercetin was found to
reduce cardiotoxicity and dyslipidemia by attenuating cardiac
oxidative stress and lipid parameters [169].
Rutin. Rutin (the glycoside between the quercetin and the
disaccharide rutinose) improves cholesterol level in different
hypercholesterolemic [170, 171] and dyslipidemic [172, 173]
rodent models. Panchal et al. have shown that rutin supple-
mentation ameliorates blood cholesterol level, cardiac struc-
ture, function, inflammation, and oxidative stress related
to high carbohydrate high-fat-induced dyslipidemia [173].
In a streptozotocin-induced diabetes model associated with
hyperlipidemia, rutin attenuated serum cholesterol level and
myocardial necrosis and improved left ventricular dysfunc-
tion [174]. It was also reported that rutin exerts cardioprotec-
tion by attenuating oxidative stress and dyslipidemia induced
by high fluoride administration in rats [172].
Silymarin. Silymarin is a mixture of three flavonolignans
(silibinin, silydianin, and silychristin) extracted from milk
thistle seeds (Silybum marianum). Krecˇman et al. demon-
strated that silymarin prevented the development of hyper-
cholesterolemia in high-cholesterol-fed rats [175]. They have
also shown that silibinin itself was not as effective as sily-
marin. Others also reported that silymarin or its fraction
decreased total and LDL cholesterol and attenuated oxidative
stress in the plasma [176–178]. The effect of silymarin on
hypercholesterolemia-induced myocardial oxidative stress
is not yet investigated, but some studies indicate that
silymarin exerts cardioprotection against high-cholesterol-
mediated oxidative stress. Silymarin attenuates myocardial
ischemia/reperfusion injury by modulating oxidative stress
[179] and silibinin has a direct antioxidant effect on H9c2
cardiac cells against oxidative stress [180]. Moreover, silibinin
was reported to improve both plasma and cardiac cholesterol
content and attenuate oxidative markers and degenerative
changes in the heart of animals exposed to arsenic [181].
In this study, silibinin prevented cardiac oxidative stress by
inhibiting the induction of prooxidants (e.g., NOX2 and
NOX4) and enhancing antioxidants.
Naringin and Hesperidin. Naringin and hesperidin are nat-
ural flavonglycosides in citrus fruits. Many studies reported
hypocholesterolemic effect of naringin and hesperidin in ani-
mal models [182–188] and in a clinical study [189]. However,
in moderately hypercholesterolemic subjects, naringin and
hesperidin failed to lower serum cholesterol [190]. Alam
et al. have published that naringin improves ventricular
diastolic dysfunction, cardiac inflammatory cell infiltration,
and plasma cholesterol in high carbohydrate, high-fat-fed
rats [182]. Recently, naringin has been shown to protect
against hypercholesterolemia-induced oxidative stress in the
heart [191].The study has demonstrated that naringin amelio-
rates cardiac lipid accumulation and cardiac oxidative stress
markers by enhancing enzymatic and nonenzymatic antiox-
idants. Moreover, tissue and serum markers of cholesterol-
induced cardiac damage were also attenuated by naringin
supplementation [191]. Although hesperidin was reported to
protect against cardiac injury induced by doxorubicin [192]
or ischemia [193, 194], its role in cholesterol-induced cardiac
oxidative stress is not known.
4.2.4. Resveratrol. Pleiotropic beneficial effects of the poly-
phenol resveratrol (food sources include the skin of grapes,
blueberries, raspberries, and mulberries) have been exten-
sively studied and many publications indicate its protective
function on cholesterol-induced cardiac oxidative stress. A
direct antioxidant effect of resveratrol was demonstrated
on H9c2 cardiac cells [195]. Louis et al. have demonstrated
that resveratrol ameliorates cardiac relaxation dysfunction
in high-fat-fed rats with hypercholesterolemia [196]. They
have also shown reduced oxidative stress and inflammatory
markers in the serumas a result of resveratrol treatment [196].
In hypercholesterolemic rats with normal cardiac function,
resveratrol improved postischemic recovery of the heart
[197]. Large animal studies from the same research group
reported that resveratrol improved high-cholesterol and
chronic ischemia-induced cardiac dysfunction and oxidative
damage of myocardial proteins [198–200]. The group also
described that resveratrol improved high-cholesterol-
induced myocardial dysfunction without decreasing protein
oxidation in the absence of ischemia [198]. Chu et al. have
shown that red wine ameliorates cardiac dysfunction and
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oxidative stress in hypercholesterolemic swine subjected
to chronic ischemia [50]. Resveratrol was reported to
improve lipid profile and cardiac dysfunction related to
hyperlipidemia in streptozotocin-induced diabetes [201].
Finally, these results may promote new studies focusing on
cholesterol-induced cardiac oxidative stress.
4.2.5. Grape Seed. Grape seed and skin are rich in natural
antioxidants, so these are possible supplements to alleviate
hypercholesterolemia-induced oxidative stress. In a high-
fat-induced obesity model, grape seed extract was shown
to improve lipid profile and prevent postischemic heart
dysfunction and cardiac lipid accumulation along with atten-
uated oxidative stress [202, 203]. Lee et al. reported that
grape skin ameliorates total serum antioxidant capacity of
rats with high-fat diet and low-fat diet [204]. Antioxidant
effect of grape seed was tested on cardiomyoblast H9c2 cell
culture [205], where it increased endogenous antioxidant
systems and prevented ROS-induced apoptosis [205]. In vivo
pretreatment with grape seed proanthocyanidins improved
postischemic functional recovery and reduced ROS pro-
duction in normocholesterolemic rats [206] and partially
restored the harmful cardiac effects of hypercholesterolemia
via their ability to reduce ROS in the myocardium [207].
4.2.6. Sour Cherry Seed Extract. Based on the observation
that cherries contain bioactive phytochemicals, for example,
phenolics and anthocyanins, which are reported to pos-
sess antioxidant, anti-inflammatory, anticancer, antidiabetic,
and antiobesity properties, Tosaki and his group hypothe-
sized that the seed kernel of sour cherry (Prunus cerasus)
may contain different bioactive constituents [208]. They
demonstrated that kernel extract obtained from sour cherry
seed improves postischemic cardiac functional recovery and
the incidence of ventricular fibrillation and tachycardia in
isolated working rat hearts [209]. Moreover, sour cherry
seed extract-induced improvement in cardiac function after
ischemia/reperfusion along with decreased atherosclerotic
plaque formation and infarct size was also observed in hyper-
cholesterolemic New Zealand rabbits fed a 2% cholesterol-
enriched diet for 16 weeks [210]. In this model, the authors
demonstrated an increased HO-1 and cytochrome c oxi-
dase III protein expression following administration of sour
cherry seed extract as a possible mechanism of action [210,
211].
4.2.7. Spices. Aqueous extracts of certain spices including
garlic (Allium sativum), ginger (Zingiber officinale), and
cayenne pepper (Capsicum frutescens) as well as their mix-
ture were shown to attenuate cardiac lipid peroxidation
induced by high-cholesterol, high-fat diet in a rat model
of hypercholesterolemia [20]. Moreover, in the same study,
hypercholesterolemia-induced decrease in the myocardial
activities of antioxidant enzymes (i.e., SOD, glutathione
peroxidase, and glutathione reductase) was also markedly
attenuated by administration of the individual spices as well
as their combination [20].
4.2.8. Red PalmOil. Redpalmoil (RPO) is a product from the
fruits of the oil palm tree (Elaeis guineensis). RPO depending
on the producer consists of about 51% saturated fatty acids
(SFAs), 38% monounsaturated fatty acids (MUFAs), 11%
polyunsaturated fatty acids (PUFAs), and a spectrum of
antioxidative carotenoids with tocopherols and tocotrienols
as the major constituents [212]. Other minor components
present in this oil are ubiquinones (mainly CoQ10) and phy-
tosterols. Red palm oil is therefore a natural carotenoid rich
oil that has the potential to act as a very potent antioxidant
[213]. Red palm oil contains the highest concentration of
tocotrienols compared with other vegetables or plants and
Serbinova et al. showed that tocotrienols can be 40–60 times
more potent as antioxidants than tocopherols [214].
Van Rooyen’s research group investigated the effect of
dietary administration of RPO on the heart. They showed
that prolonged dietary feeding with RPO-supplemented diet
(∼7 g RPO/kg diet) protected the heart against ischemia/re-
perfusion injury in rats. They used isolated heart mod-
els, perfused both in Langendorff technique [215–218] and
working mode [212, 219], showing the vascular-independent
direct cardioprotective effects of RPO. RPO administration
improved cardiac function during reperfusion [212] and
decreased infarct size [215, 216]. The real advantage of RPO
administration became apparent when RPO was given to
hyperlipidemic rats. Hyperlipidemia was induced by feeding
animals with 2% cholesterol-enriched diet for 5–9 weeks.
This model was characterized by mild cholesterol elevation
but a marked decrease of cardiac performance. RPO was
able to markedly increase aortic output recovery after 25min
global ischemia [219, 220], or infarct size [215] after 30min
global ischemia, showing the protective effect of RPO in the
presence of comorbidities.
The proposed mechanism by which RPO exerts its
cardioprotective effect in animals fed high-cholesterol diet
is not fully understood. Supplementation with RPO in the
presence of potentially harmful cholesterol showed no sig-
nificant difference in serum cholesterol level; therefore, its
protection cannot be explained by the cholesterol-lowering
effect of RPO. It is proposed that the protective effect
of RPO in high-cholesterol diet may be associated with
either the RPO antioxidant characteristics and/or changes
in the fatty acid composition of the myocardium during
ischemia/reperfusion.
4.3. Promising Novel Approaches to Modulate
Hypercholesterolemia-Induced Oxidative Stress
4.3.1. miRModulation. Only 3% of the human genome codes
for proteins and the remaining part consist of noncoding
RNAs including short microRNAs (miRNAs, miRs; approx-
imately 18–25 nucleotides in length) [221, 222]. miRNAs can
inhibit the translation or promote mRNA degradation by
binding to specificmRNAs according to the complementarity
of their seed sequences [223]. Individual miRNAsmay simul-
taneously target multiple mRNAs. However, the expression
of individual mRNAs can be regulated by multiple miRNAs.
Therefore, miRNAsmay act as fine tuners or as on/off switch-
ers of gene expression [223, 224]. Dysregulation of miRNAs
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Table 1: Regulation of miRNAs in hyperlipidemia.
miRNA Regulation ofmiRNA Organ Target
Regulation of
target Role References
let-7g down Aorta ox-LDL receptor 1 up ox-LDL cholesterol uptake [24]
miR-25 down Heart NOX4 up Oxidative stress [8]
miR-33 up Liver,macrophages ABCA1 down
Reverse cholesterol
transport [25]
miR-33 up Peripheraltissues ABCG1 down
Reverse cholesterol
transport [25, 26]
miR-33 down Liver Fatty acidsynthesis down VLDL synthesis [27]
miR-33 down Liver Fatty acidoxidation up VLDL synthesis [27]
miR-144 up Liver ABCA1 down Reverse cholesteroltransport [28]
miR-223 up Liver HMG-CoAsynthase 1 down Cholesterol biosynthesis [29]
miR-223 up Liver Scavengerreceptor B1 down HDL cholesterol uptake [29]
miR-208a up Heart MED13 down Glucose tolerance [30]
miR-378 and
miR-378∗ up Liver MED13 down Glucose tolerance [31]
miR-378 and
miR-378∗ up
Insulin
dependent
tissues
Fatty acid
oxidation down Obesity [31]
ABC: ATP-binding cassette transporter; HDL: high density lipoprotein; VLDL: very low density lipoprotein; MED: mediator complex subunit; NOX: NADPH
oxidase.
in pathological conditionsmay alter gene networks; therefore
miRNA replacement or antisense inhibition therapy offers
a new approach to treating diseases by modulating gene
pathways rather than single molecular targets [222].
In recent years, a growing body of evidence has demon-
strated that miRNAs play a role in the development of
numerous cardiovascular diseases. Several excellent reviews
focus on miRNAs as diagnostic markers and potential ther-
apeutic targets in cardiac pathologies including acute coro-
nary syndrome [221, 225] and remodelling after myocardial
infarction as well as heart failure [25, 221, 224, 226–228]
and their risk factors including hypercholesterolemia [229],
diabetes mellitus [230, 231], arterial hypertension [232, 233],
atherosclerosis [234, 235], and aging [227].
Hypercholesterolemia is a well-known risk factor of
cardiovascular diseases and it leads to increased oxida-
tive/nitrative stress in the myocardium. Experimental data
are very limited on the regulatory role of miRNAs in
hypercholesterolemia-induced oxidative/nitrative stress in
cardiac pathologies. We have previously shown that the
myocardial downregulation of miR-25 results in the upreg-
ulation of NADPH oxidase 4 (NOX4) mediating oxida-
tive/nitrative stress and subsequent myocardial dysfunction
in male hypercholesterolemic rats [8] (Table 1). Moreover,
in a recent study, decreased circulating miRNA-25 level has
been related to the level of oxidative stress indicators in septic
patients and the clinical accuracy of miRNA-25 for sepsis
diagnosis has been reported to be better than C-reactive pro-
tein [236]. In addition, downregulation of miR-25 expression
has been demonstrated in cardiac hypertrophy induced by
transverse aortic constriction surgery inmice; however, there
is no data published on increased oxidative/nitrative stress
or cholesterol levels in that study [237]. Furthermore, in vivo
inhibition of miR-25 by a specific antagomir resulted in the
spontaneous development of cardiac dysfunction and sensi-
tized the myocardium to develop heart failure in a Hand2-
dependent manner [237]. In contrast, inhibition of overex-
pressed miR-25 was reported to ameliorate contractile dys-
function by improving sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA)2a activity and Ca2+ handling in chronic
heart failure induced by transverse aortic constriction surgery
in mice as well as in failing human heart samples; however,
data on the presence of hypercholesterolemia in humanswere
lacking in this study [238].
It is well known that hyperlipidemia, obesity, metabolic
syndrome, and heart failure are associated with abnormal
cardiac metabolism. In obese mice, a heart specific miRNA,
miR-208a, has been reported to negatively regulate mediator
complex subunit 13 (MED13), which controls transcription
by thyroid hormone and other nuclear hormone receptors
[30] (Table 1). Indeed, cardiac-specific overexpression of
MED13 or pharmacologic inhibition of miR-208a in mice
has been demonstrated to confer resistance to high-fat diet-
induced obesity and improve systemic glucose tolerance
[30] (Table 1). Moreover, mice genetically lacking miR-378
and miR-378∗ have been shown to be resistant to high-fat
diet-induced obesity and exhibit enhanced mitochondrial
fatty acid metabolism and elevated oxidative capacity of
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insulin-target tissues [31] (Table 1). Interestingly, MED13
and carnitine O-acetyltransferase, a mitochondrial enzyme
involved in fatty acidmetabolism, are among themany targets
of miR-378 and miR-378∗ [31] (Table 1). Thus, these miRNAs
provide potential therapeutic targets in hyperlipidemia and
metabolic disorders, although their myocardial function
needs to be further investigated.
High level of LDL cholesterol and low level of HDL
cholesterol are both well known as independent risk factors
of coronary artery diseases. miRNAs have been shown to reg-
ulate lipoprotein metabolism and their pro-/antiatherogenic
effects at many levels in different tissues as reviewed by others
[25, 222, 229]. Cholesterol efflux from cells is the first step
in reverse cholesterol transport to the liver carried out by
HDL. miR-33 has been reported to modulate cholesterol
efflux by repressing the expression of ATP-binding cassette
transporter (ABC) A1 in the liver and ABCA1 as well as
ABCG1 in peripheral tissues [25] (Table 1). Moreover, anti-
miR-33 therapy was shown to induce the expression of
ABCA1 in macrophages in atherosclerotic plaques thereby
reducing the plaque size and local inflammation in mice
[26] (Table 1). In addition, anti-miR-33 therapy in nonhuman
primates increased the expression of miR-33 target genes
involved in fatty acid oxidation and reduced the expression of
genes associated with fatty acid synthesis in the liver resulting
in a marked suppression of plasma VLDL triglyceride levels
[27] (Table 1). Another miRNA, miR-144, has been reported
to decrease hepatic ABCA1 expression and plasma HDL
cholesterol levels [28] (Table 1). Moreover, miR-223 has been
demonstrated to reduce HDL cholesterol uptake by decreas-
ing the expression of scavenger receptor B1 and to decrease
cholesterol biosynthesis through the direct repression of
HMG-CoA synthase 1 in the liver of ApoE−/− mice [29]
(Table 1). Furthermore, genetic ablation of miR-223 resulted
in elevated hepatic and plasma total cholesterol levels as well
as increased HDL cholesterol levels and particle size [29]
(Table 1). Interestingly, aortae of mice fed with high-fat diet
for 6 weeks and human hypercholesterolemic sera showed
decreased let-7g expression [24] (Table 1). In the same study
a negative feedback regulation has been identified between
oxidized LDL receptor 1 and let-7g in primary human aortic
smooth muscle cells [24] (Table 1).
Certain microRNAs have been implicated in cellu-
lar responses to oxidative/nitrative stress in cardiovascular
pathologies in preclinical studies [33, 238–241]. Many miR-
NAs, including miR-21 and miR-199a, have been reported
to play a role in cardiomyocyte survival during ischemia
[33, 242] (Table 1). Moreover, injection of AAV9 vectors
expressing miR-199 and 590 into the peri-infarcted area
of the myocardium could reduce infarct size and improve
regeneration after myocardial infarction in mice [243]. We
and others have shown that several miRNAs includingmiR-1,
miR-21,miR-125b∗, miR-139-3p,miR-139-5p,miR-181a,miR-
188,miR-192,miR-212,miR-320,miR-487b, andmiR-532 play
a role in the mechanism of ischemic preconditioning con-
ferring cardioprotection after ischemia/reperfusion injury
[32, 34] (Table 2). These miRNAs also drive the synthesis
of important cardioprotective proteins including heat shock
Table 2: miRNAs affected by ischemic pre- or postconditioning in
the heart.
miRNA I/R versuscontrol Ipre versus I/R
Ipost versus
I/R
let-7b down [32] n.a. [32] up [32]
miR-21 down [33] up [34, 35] n.a. [35],up [36]
miR-125b∗ down [32] up [32] up [32]
miR-139-3p down [32] up [32] up [32]
miR-181a down [32] down [32] up [32]
miR-199a down [33] up [34] no data
miR-328 down [32] n.a. [32] up [32]
miR-335 down [32] n.a. [32] up [32]
miR-503 down [32] n.a. [32] up [32]
let-7e n.a. [32] n.a. [32] up [32]
let-7i n.a. [32] n.a. [32] up [32]
miR-1 n.a. [32],down [37, 38] up [34]
up [32, 37],
down [35]
miR-139-5p n.a. [32] up [32] n.a. [32]
miR-188 n.a. [32] up [32] up [32]
miR-192 n.a. [32] up [32] n.a. [32]
miR-212 n.a. [32] up [32] n.a. [32]
miR-532 n.a. [32] up [32] up [32]
miR-133a up [34],down [37] no data up [37]
miR-208a up [32, 34] n.a. [32] down [32]
miR-320 up [34],down [32] down [32] down [32]
miR-487b up [32] down [32] n.a. [32]
I/R: ischemia/reperfusion; Ipre: ischemic preconditioning; Ipost: ischemic
postconditioning; n.a.: not affected.
protein- (HSP-) 70, endothelial and inducible NOS, HSP-20,
NAD-dependent deacetylase sirtuin-1 (Sirt1), and hypoxia-
inducible factor 1a [34]. miRNAs are also associated with
the protective effect of ischemic postconditioning against
myocardial ischemia/reperfusion injury. Heart specific miR-
1 and miR-133a have been associated with playing a role
in the cardioprotection conferred by ischemic postcondi-
tioning through the regulation of apoptosis-related genes
[35, 37]; however, the regulation of miR-1 by ischemic post-
conditioning is controversial [32, 35, 37] (Table 2). Another
miRNA, miR-21, has been demonstrated to be implicated in
ischemic postconditioning, though its role in cardioprotec-
tion is controversial [35, 36] (Table 2). In addition, loss of
the miR-144/451 cluster function has been shown to limit
the cardioprotective effect of ischemic preconditioning by
upregulating Rac-1-mediated oxidative stress signaling [38].
Therefore, further preclinical and clinical studies are needed
to investigate the role of miRNAs in ischemia/reperfusion
injury and myocardial stress adaptation in healthy and
diseased conditions, including hypercholesterolemia.
miRNAs exert control over diverse metabolic pathways
and are frequently dysregulated in cardiovascular diseases.
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Thus, miRNAs have become a class of promising thera-
peutic targets. Until miRNA-based therapeutic interventions
become a reality in clinical medicine many questions should
be answered in preclinical and clinical studies [244]. Better
technologies and more applicable in vitro and in vivomodels
of human diseases should be developed to identify and
validate directmRNA targets ofmiRNAs [244]. Furthermore,
improved understanding of the mechanism of action in
each tissue type is necessary. Moreover, development of
organ specific delivery methods for miRNA mimics and
anti-miR oligonucleotides are needed [244]. Nevertheless,
assessment of the efficacy and safety including the analysis
of the off-target effects ofmiRNA-based therapeutic tools and
understanding of the long-term effects ofmiRNAmodulation
in vivo are of key importance in the future [244].
4.3.2. Peroxynitrite Scavenging. Peroxynitrite is formed by
the rapid reaction of superoxide and NO and is respon-
sible for a variety of deleterious effects in cardiovascular
pathologies [245]. Therefore, development of peroxynitrite
scavengers or compounds catalyzing the decomposition of
peroxynitrite to nontoxic products has been an emerging
field in the last decade [245]. Formation of peroxynitrite
in the heart of hypercholesterolemic animals has been
demonstrated in various experimental models [6, 8, 246].
The beneficial effect of decomposition of cardiac peroxyni-
trite leading to improved cardiac function in experimental
hypercholesterolemia was also shown [6, 246]. In isolated
working hearts from Wistar rats or apoB100 transgenic
mice fed with cholesterol-enriched diet, deterioration of
cardiac function characterized by increased left ventricular
end-diastolic pressure (LVEDP) or decreased aortic flow
was demonstrated, respectively [6, 246]. Pretreatment of
the animals with the peroxynitrite decomposition catalyst
FeTPPS (5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato
iron (III), chloride) before isolation of the hearts resulted
in an improved LVEDP and aortic flow, respectively [6,
246]. Whether application of peroxynitrite scavengers would
reverse impaired conditioning in hypercholesterolemic ani-
mals remains to be addressed in future studies.
4.3.3. Hydrogen. Recent advances in basic and clinical
research have indicated that hydrogen gas is an impor-
tant physiological regulatory factor with antioxidant, anti-
inflammatory, and antiapoptotic protective effects, and thus
the application of molecular hydrogen as a therapeutic med-
ical gas in diverse disease conditions has become a feasible
therapeutic strategy [247]. Hydrogen is suggested to be an
efficient, nontoxic, highly bioavailable, and low-cost antiox-
idant supplement for patients with pathological conditions
involving ROS-induced oxidative stress [248]. Therapeutic
hydrogen can be applied by different delivery methods
including inhalation of hydrogen gas, drinking hydrogen
dissolved in water, and injection with hydrogen-saturated
saline [247]. In the heart, hydrogen attenuated doxorubicin-
induced heart failure in rats [249], cardiac dysfunction in
streptozotocin-induced diabetic mice [250], rat cardiac cold
ischemia/reperfusion injury [251], and left ventricular hyper-
trophy in spontaneous hypertensive rats [252] and exerted
cardioprotective effects on isoproterenol-inducedmyocardial
infarction in rats [253]. Moreover, inhalation of hydrogen
attenuated increased serum cholesterol, cardiac superoxide
production, and left ventricular remodeling induced by
intermittent hypoxia inmice [254]. Similarly, consumption of
hydrogen-rich water beneficially affected serum cholesterol
status and oxidative stress markers in patients with potential
metabolic syndrome or isolated hypercholesterolemia [255,
256]. These promising results should be confirmed.
4.3.4. Miscellaneous Examples. Diphenyl diselenide has been
recently reported to attenuate hypercholesterolemia-associ-
ated cardiac oxidative stress and increase antioxidants with-
out affecting plasma level of cholesterol in LDL receptor
knockout mice [257].
Local infiltration of neuropeptide Y to hypercholes-
terolemic swine heart subjected to ischemia was shown to
ameliorate cardiac diastolic dysfunction probably by decreas-
ing oxidative stress and fibrosis and increasing cell survival in
the heart [258, 259].
4.4. Physical Activity. A dramatic decrease in an individual’s
physical activity is the most obvious change accompanied
by western-type lifestyle and technical development in the
industrial countries. Physical inactivity is a risk factor and
promotes development of civilization diseases. It is widely
accepted that physical activity positively influences a variety
of clinical diseases including obesity, metabolic syndrome,
dys- and hyperlipidemias, diabetes, and cardiovascular dis-
eases [260, 261].
Hypercholesterolemia is accepted as one of the most
important risk factors in the development of different vas-
cular and heart diseases. Physical activity and change in
lifestyle are the first choices in normalization of patient’s
high blood cholesterol level. The mechanisms by which
physical activity prevents development of metabolic diseases
are rather diverse. The primary effect of physical activity
can be seen in a metabolic level. Due to higher energy
demand, physical activity intensively increases weight loss.
A weight loss of 10 percent can significantly lower the
risk of cardiovascular diseases by reversing hyperlipidemia.
Moreover, by increasing the catabolic rate of the body,
physical exercise positively influences carbohydrate and lipid
metabolism and blood lipid profile. Thus, exercise training
is associated with increased reliance on lipids as an energy
substrate, has a systemic lipid-lowering effect, and results
in remodeling of skeletal muscle lipid metabolism toward
increased oxidation and neutral lipid storage and turnover
[262]. Physical activity has substantial effects on the liver
metabolism as well, modifying lipoprotein levels to a more
healthy composition. These effects can be enhanced by
using concurrent dietary restrictions; for example, a low-
cholesterol diet definitely helps to regulate lipid profile in
the body. Regular participation in physical activity as well
as a single exercise session can positively alter cholesterol
metabolism [263]. Exercise is involved in increasing the
production and action of several enzymes that function to
enhance the reverse cholesterol transport system [263].
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Nevertheless, physical activity has secondary effects on
the prevention of development of metabolic diseases by,
for example, modifying oxidative stress. Physical activity is
believed to be a protective modulator of oxidative stress
in hyperlipidemia; however, high intensity physical exercise
itself can definitely increase oxidative stress in patients [264–
266]. Two key free radicals are the most important during
physical activity, that is, superoxide and NO. The exact
sources of these radicals are not fully known; however,
mitochondria are often cited as the predominant source of
ROS inmuscle cells. Investigators have often assumed that the
increased ROS generation that occurs inmuscle fibers during
contractile activity is directly related to the elevated oxygen
consumption. However, growing evidence argues against
mitochondria being the dominant source of ROS production
in skeletal muscle during exercise [264]. Another possible
source is NADPH oxidase, which is normally quiescent,
but when it becomes activated, during muscle contraction
or when recruited for antimicrobial and proinflammatory
events, it can generate large amounts of superoxide [264, 267,
268]. Since the discovery that contracting skeletal muscles
produce ROS, many investigators have assumed that skeletal
muscle provides the major source of free radical and ROS
generation during exercise. Nonetheless, other tissues such
as the heart, lungs, or blood may also contribute to the total
body generation of ROS during exercise [264]. Thus the
increased catabolic process together with multiplied oxygen
consumption in both skeletal and cardiac muscles during
exercise exacerbates superoxide production.
The other major free radical which contributes to oxida-
tive/nitrative stress isNO.NO is responsible for the relaxation
of vessels [269] and plays an important role inmatching tissue
perfusion to demand [270]. The release of nitric oxide by
the endothelial cell can be upregulated by exercise [261, 271].
However, hypercholesterolemia impairs endothelial function
(e.g., the NO-cyclic GMP-phosphodiesterase 5 pathway),
limits shear stress-induced vasodilation, and is therefore
expected to reduce exercise-induced vasodilation [272].
In addition to the modulation of ROS and RNS pro-
duction, physical exercise may also affect the antioxi-
dant defense systems. McCommis et al. have demonstrated
that familial hypercholesterolemia reduces mitochondrial
antioxidants, increases mitochondrial oxidative stress, and
enhances themitochondrial permeability transition response
in the porcine myocardium [19]. They also showed that
exercise training can reverse these detrimental alterations
without altering serum cholesterol level [19].
In spite of the extensive research, the cardioprotective
effect of exercise which is mediated by redox changes
is still a question of debate. Several studies showed that
hyperlipidemia impairs exercise capacity itself [273] or
the effect of physical activity [272, 274, 275]. However,
a number of exercise programs have effectively reversed
hypercholesterolemia-induced changes mainly within the
vasculature by improving NO bioavailability in both animal
studies and humans [276–281].
The exact explanation why physical activity, which simi-
larly to hyperlipidemia leads to an increased oxidative stress,
is able to protect the heart in hypercholesterolemia is rather
difficult. One possible answer is that during exercise an
intensive but only a temporary increase of oxidative stress
occurs resulting in a possibility for cardiac adaptation by an
improved enzymatic and nonenzymatic antioxidant capacity,
cytoprotection, aerobic capacity, training-induced muscular
adaptation, mitochondrial biogenesis, and so forth [268]. In
hypercholesterolemia with no exercise, the continuously ele-
vated oxidative/nitrative stress, however, does not allow the
completion of cardioprotective mechanisms. End-effectors
of cardioprotection involve the activation of ATP-sensitive
K+-channels (KATP). We have recently demonstrated that a
cholesterol-enriched diet inhibited cardioprotection induced
by KATP activators and that cholesterol diet may impair
cardiac KATP channels [282]. It is well accepted that the
opening of KATP channels generates ROS; however, an
ambient oxidative state also modifies redox-sensitive KATP
channels, as superoxide, hydrogen peroxide, and peroxyni-
trite open KATP channels in the heart. These results show
that increased oxidative stress interferes with KATP channel
function and thereforemight explain why cardioprotection is
lost in hyperlipidemia.
Increased physical activity can be alsomimicked in exper-
imental animal models by applying ventricular overdrive
pacing of the heart, a method that was reported to induce
both preconditioning and postconditioning by increasing the
oxygen demand (relative hypoxia) instead of limiting oxygen
supply (absolute hypoxia) in isolated heart models [283–
285]. Peroxynitrite plays an important role in different con-
ditionings induced by either ischemia or ventricular pacing
[11, 286]. It is known that experimental hypercholesterolemia
blocks the cardioprotective effect of postconditioning at least
in part via deterioration of postconditioning-induced early
increase in peroxynitrite formation during reperfusion [11].
Thus one can speculate that regular physical exercise is able
to restore the protective effects of pre- or postconditioning in
hypercholesterolemia via modifying cardiac oxidative stress
and by beneficially altering lipid profile in the blood.
In addition to emphasizing the importance of regular
exercise, novel future directions have been implicated to take
advantage of exercise-induced benefits. Thus development of
new “exercise mimetics” has a promising role in the future for
treatment of patients [287].
5. Conclusions
Oxidative and nitrative stress has been implicated as a
pathophysiological mechanism of cardiovascular diseases;
however, there is still no breakthrough regarding the use
of general antioxidant therapies in clinical practice. The
possible reasons for these disappointing results and some
promising aspects of potential antioxidant therapy have been
discussed in detail recently [288]. Although hypercholestero-
lemia occurs frequently in the adult population, the number
of publications investigating myocardial oxidative/nitrative
stress and its cardiac consequences is relatively limited
especially in humans. This is unfortunate, as patients with
hypercholesterolemia are at an increased risk for severe
pathological conditions such as myocardial infarction and
heart failure and hypercholesterolemia has been shown
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to interfere with endogenous cardioprotective mechanisms.
Therefore, finding proper approaches to beneficially affect
hypercholesterolemia and its myocardial consequences is
crucial.These reasons warrant further preclinical and clinical
studies to better understand the pathological events in the
heart relating to hypercholesterolemic conditions and to
find the best approaches to interact. Moreover, many of
the potential modulators of oxidative/nitrative stress require
further development to optimize their effects for application
in hypercholesterolemia.
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